Triple inhaled therapy for asthma in Canada

References

• Asthma Canada. Asthma facts and statistics. www.asthma.ca
   Google Scholar
• Yang CL, Hicks EA, Mitchell P, et al. Canadian Thoracic Society 2021 Guideline update: Diagnosis and management of asthma in preschoolers, children and adults. Can J Respir Crit Care Sleep Med. 2021;5(6):348–361. doi:10.1080/24745332.2021.1945887.
   Web of Science ®Google Scholar
• McIvor RA, Boulet LP, FitzGerald JM, Zimmerman S, Chapman KR. Asthma control in Canada: no improvement since we last looked in 1999. Can Fam Phys. 2007;53(4):672–677.
   PubMedGoogle Scholar
• Sadatsafavi M, McTaggart-Cowan H, Chen W, Mark Fitzgerald J. Quality of life and asthma symptom control: room for improvement in care and measurement. Value Health. 2015;18(8):1043–1049. doi:10.1016/j.jval.2015.07.008.
   PubMed Web of Science ®Google Scholar
• Busse WW, Kraft M. Current unmet needs and potential solutions to uncontrolled asthma. Eur Respir Rev. 2022;31:210176. doi:10.1183/16000617.0176-2021.
   PubMed Web of Science ®Google Scholar
• de Marco R, Locatelli F, Cazzoletti L, Bugianio M, Carosso A, Marinoni A. Incidence of asthma and mortality in a cohort of young adults: a 7-year prospective study. Respir Res. 2005;6(1):95. doi:10.1186/1465-9921-6-95.
   PubMed Web of Science ®Google Scholar
• To T, Zhu J, Williams DP, et al. Frequency of health service use in the year prior to asthma death. J Asthma. 2016;53(5):505–509. doi:10.3109/02770903.2015.1064949.
   PubMed Web of Science ®Google Scholar
• Sadatsafavi M, Chen W, Tavakoli H, Rolf JD, Rousseau R, FitzGerald JM. Saving in medical costs by achieving guideline-based asthma symptom control: a population-based study. Allergy. 2016;71(3):371–377. doi:10.1111/all.12803.
   PubMed Web of Science ®Google Scholar
• Zafari Z, Sadatsafavi M, Chen W, Fitzgerald JM. The projected economic and health burden of sub-optimal asthma control in Canada. Respir Med. 2018;138:7–12. doi:10.1016/j.rmed.2018.03.018.
   PubMed Web of Science ®Google Scholar
• Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis. 1991;143(6):1317–1321. doi:10.1164/ajrccm/143.6.1317.
   PubMedGoogle Scholar
• Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836–844. doi:10.1164/rccm.200401-033OC.
   PubMed Web of Science ®Google Scholar
• Newton R, Giembycz MA. Understanding how long-acting β2-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma – an update. Br J Pharmacol. 2016;173(24):3405–3430. doi:10.1111/bph.13628.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Athma. Global strategy for asthma management and prevention. 2022. www.ginasthma.org
   Google Scholar
• Aaron SD, Vandemheen KL, Boulet LP, et al. Overdiagnosis of asthma in obese and nonobese adults. CMAJ. 2008;179(11):1121–1131. doi:10.1503/cmaj.081332.
   PubMed Web of Science ®Google Scholar
• Tilles SA. Differential diagnosis of adult asthma. Med Clin North Am. 2006;90(1):61–76. doi:10.1016/j.mcna.2005.08.004.
   PubMed Web of Science ®Google Scholar
• Express Scripts Canada. Prescription Drug Trend Report. 2019. https://www.express-scripts.ca/sites/default/files/2020-12/Express_Scripts_Canada_2018_Prescription_Drug_Trend_Report_FINAL.pdf. Accessed July 12, 2022.
   Google Scholar
• Amin S, Soliman M, McIvor A, Cave A, Cabrera C. Understanding patient perspectives on medication adherence in asthma: a targeted review of qualitative studies. Patient Prefer Adherence. 2020;14:541–551. doi:10.2147/PPA.S234651.
   PubMed Web of Science ®Google Scholar
• D'Ancona G, Weinman J. Improving adherence in chronic airways disease: are we doing it wrongly? Breathe (Sheff). 2021;17(2):210022. doi:10.1183/20734735.0022-2021.
   PubMedGoogle Scholar
• Advisory Council on the Implementation of National Pharmacare. A Prescription for Canada: Achieving Pharmacare for All. Ottawa, ON: Government of Canada; 2019.
   Google Scholar
• Price D, Chrystyn H, Kaplan A, et al. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol Res. 2012;4(4):184–191. doi:10.4168/aair.2012.4.4.184.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Facciolo F, Page C, Cazzola M, Calzetta L. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: synergy of triple combination therapy on human airway smooth muscle ex vivo. Br J Pharmacol. 2020;177(5):1150–1163. doi:10.1111/bph.14909.
   PubMed Web of Science ®Google Scholar
• Chapman KR. The history of antimuscarinic bronchodilator therapy. In: Spector SL, ed. Anticholinergics in Clinical Allergy Practice Lung Biology in Health and Disease. New York: Marcel Dekker; 1999:155–169.
   Google Scholar
• Rebuck AS, Chapman KR, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med. 1987;82(1):59–64. doi:10.1016/0002-9343(87)90378-0.
   PubMed Web of Science ®Google Scholar
• Rebuck AS, Gent M, Chapman KR. Anticholinergic and sympathomimetic combination therapy of asthma. J Allergy Clin Immunol. 1983;71(3):317–323. doi:10.1016/0091-6749(83)90086-6.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bhutani M, Hernandez P, et al. Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Can J Respir Crit Care Sleep Med. 2019;3(4):210–232. doi:10.1080/24745332.2019.1668652.
   Web of Science ®Google Scholar
• Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016;2016(1):CD011721. doi:10.1002/14651858.CD011721.pub2.
   PubMedGoogle Scholar
• Chari VM, McIvor RA. Tiotropium for the treatment of asthma: patient selection and perspectives. Can Respir J. 2018;2018:3464960. doi:10.1155/2018/3464960.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–1207. doi:10.1056/NEJMoa1208606.
   PubMed Web of Science ®Google Scholar
• SPIRIVA Product Monograph. 2022. https://pdf.hres.ca/dpd_pm/00065560.PDF.
   Google Scholar
• Zhang S, King D, Rosen VM, Ismaila AS. Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD: a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:417–438. doi:10.2147/COPD.S234823.
   PubMed Web of Science ®Google Scholar
• Enerzair Product Monograph. 2021. https://pdf.hres.ca/dpd_pm/00063748.PDF
   Google Scholar
• Trelegy Product Monograph. 2022. https://pdf.hres.ca/dpd_pm/00068965.PDF
   Google Scholar
• European Medicines Agency. Trimbow: EPAR - medicine overview. https://www.ema.europa.eu/en/medicines/human/EPAR/trimbow. 2017. Accessed April 5, 2023.
   Google Scholar
• Bibliothèque et Archives nationales du Québec. RAMQ list of medications. https://www.ramq.gouv.qc.ca/sites/default/files/documents/non_indexes/liste_med_2023-05-25_en_maj.pdf. Published May 25, 2023. Accessed March 31, 2023.
   Google Scholar
• Ontario Ministry of Health. Ontario drug benefit: formulary/comparative drug index (edition 43). https://www.health.gov.on.ca/en/pro/programs/drugs/odbf_mn.aspx. 2023. Accessed May 31, 2023.
   Google Scholar
• Kaplan A, Chang K-L. Tiotropium in asthma – perspectives for the primary care physician. Postgrad Med. 2021;133(5):552–564. doi:10.1080/00325481.2020.1816329.
   PubMed Web of Science ®Google Scholar
• Busse WW, Abbott CB, Germain G, et al. Adherence and persistence to single-inhaler versus multiple-inhaler triple therapy for asthma management. J Allergy Clin Immunol Pract. 2022;10(11):2904–2913.e6. doi:10.1016/j.jaip.2022.06.010.
   PubMed Web of Science ®Google Scholar
• Averell CM, Stanford RH, Laliberté F, Wu JW, Germain G, Duh MS. Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs. J Asthma. 2021;58(1):102–111. doi:10.1080/02770903.2019.1663429.
   PubMed Web of Science ®Google Scholar
• Averell CM, Laliberte F, Duh MS, Wu JW, Germain G, Faison S. Characterizing real-world use of tiotropium in asthma in the USA. J Asthma Allergy. 2019;12:309–321. doi:10.2147/JAA.S216932.
   PubMed Web of Science ®Google Scholar
• Collier DJ, Wielders P, Van Der Palen J, et al. Critical error frequency and the impact of training with inhalers commonly used for maintenance treatment in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2020;15:1301–1313. doi:10.2147/COPD.S224209.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000–1012. doi:10.1016/S2213-2600(20)30190-9.
   PubMed Web of Science ®Google Scholar
• Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, Phase IIIb, non-inferiority study (ARGON). Respir Med. 2020;175:106186. doi:10.1016/j.rmed.2020.106186.
   PubMed Web of Science ®Google Scholar
• Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9(1):69–84. doi:10.1016/S2213-2600(20)30389-1.
   PubMed Web of Science ®Google Scholar
• Keith PK, Koch C, Djandji M, et al. Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J. 2009;16 Suppl A(Suppl A):17a–31a. doi:10.1155/2009/145071.
   PubMedGoogle Scholar
• Fortescue R, Kew KM, Leung MT. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2020;9(9):CD011293. doi:10.1002/14651858.CD011293.pub3.
   PubMedGoogle Scholar
• Kim LHY, Saleh C, Whalen-Browne A, O'Byrne PM, Chu DK. Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis. JAMA. 2021;325(24):2466–2479. doi:10.1001/jama.2021.7872.
   PubMed Web of Science ®Google Scholar
• Singh D, Virchow JC, Canonica GW, et al. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. Respir Res. 2020;21(1):285. doi:10.1186/s12931-020-01558-y.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Braido F, Calzetta L, et al. The 5T approach in asthma: Triple Therapy Targeting Treatable Traits. Respir Med. 2022;200:106915. doi:10.1016/j.rmed.2022.106915.
   PubMed Web of Science ®Google Scholar
• Fulford B, Mezzi K, Whiting A, Aumônier S. Life-cycle assessment of the breezhaler® breath-actuated dry powder inhaler. Sustainability. 2021;13(12):6657. doi:10.3390/su13126657.
   Web of Science ®Google Scholar
• BREZTRI™ AEROSPHERE® Product Monograph. 2021. https://pdf.hres.ca/dpd_pm/00062143.PDF.
   Google Scholar
• Rogliani P, Cavalli F, Chetta A, Cazzola M, Calzetta L. Potential drawbacks of ICS/LABA/LAMA triple fixed-dose combination therapy in the treatment of asthma: a quantitative synthesis of safety profile. J Asthma Allergy. 2022;15:565–577. doi:10.2147/JAA.S283489.
   PubMed Web of Science ®Google Scholar